Canafenib/Encofenib is developed and produced by which pharmaceutical company and its background introduction

Canafenib/Encorafenib (Encorafenib) is a BRAF inhibitor, mainly used to treat patients with BRAF Patients with V600E or V600K mutated malignant melanoma and some metastatic colorectal cancer. The drug selectively inhibits the activity of mutated BRAF kinase and blocks the MAPK signaling pathway, thereby inhibiting tumor cell proliferation and survival. As a new generation of BRAF inhibitors, it is more effective when combined with MEK inhibitors, which can significantly extend progression-free survival and improve patient prognosis.

Canafenib was originally developed by Array BioPharma , an American biopharmaceutical company focused on the development of targeted therapeutic drugs for tumors and other diseases. Array BioPharma It has rich research and development experience in the field of molecular targeted drugs, and canafenib is one of the important achievements in its research and development pipeline. In 2019, Pfizer (Pfizer) completed the acquisition of Array BioPharma, which brought the global development and commercialization of canafenib into a larger-scale promotion stage.

In terms of approval progress, the U.S.FDA approved canafenib combination for the first time in2018MEKThe inhibitor bimetinib (Binimetinib) is used to treat unresectable or metastatic BRAF V600mutant melanoma. 2020In combination with cetuximab, canafenib was approved by the FDA for the treatment of BRAF V600E mutated metastatic colorectal cancer. This is an important expanded indication of this drug beyond melanoma, reflecting its diverse application value in precision tumor treatment.

Overall, canafenib’s performance from Array BioPharmaFrom research and development to commercialization after acquisition by Pfizer, it has gone through a complete R&D-clinical-promotion process. With its clear molecular target, good clinical efficacy and relatively controllable safety, canafenib has become one of the important treatment options for BRAF mutation-related tumors worldwide, and it also marks the trend of targeted drug research and development towards precision and combination development.

Reference materials:https://www.drugs.com/